HMNC Brain Health raises $50M Series B to advance two depression drugs

What's the deal? HMNC Brain Health, a family-owned German biotech, has closed a $50M Series B round. The funding will advance two psychiatry programmes — including a challenger to Johnson & JohnsonDealroom has a profile for this one. Try Dealroom →'s Spravato — into mid-stage clinical studies.

Why now? Depression remains one of the largest unmet needs in medicine, with existing treatments failing a significant share of patients. Spravato, a nasal-spray ketamine derivative approved for treatment-resistant depression, has drawn both commercial success and criticism over its side-effect profile — creating an opening for competitors with potentially cleaner alternatives.

What could go wrong? CNS drug development is notoriously risky: psychiatric trials have high placebo response rates and frequent late-stage failures. As a family-owned company, HMNC may also face constraints in raising follow-on capital compared to venture-backed peers if its programmes need more funding than expected.

The signal: HMNC Brain Health is classified as a "breakout stage" company on Dealroom, combining drug development with patented genetic tests and machine-learning-driven companion diagnostics — a precision psychiatry approach that could differentiate it in a crowded depression pipeline. The $50M raise suggests that even in a cautious funding environment, investors see room for platforms that pair novel therapeutics with biomarker-led patient selection.

Read more: endpoints.news